{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:52:30Z","timestamp":1793969550337,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtho.2026.104087","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:49:16Z","timestamp":1783666156000},"page":"104087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L)"],"prefix":"10.1016","volume":"21","author":[{"given":"Suresh S.","family":"Ramalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Gilberto","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazi\u00e9res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Poddubskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Whipple","family":"Neibauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvajit","family":"Aghera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104087_bib1","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: a decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2026.104087_bib2","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104087_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104087_bib5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.104087_bib6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104087_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jtho.2024.10.012","article-title":"Pembrolizumab with or without maintenance olaparib for metastatic squamous NSCLC that responded to first-line pembrolizumab plus chemotherapy","volume":"20","author":"Hochmair","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer","volume":"14","author":"Borghaei","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.jtho.2026.104087_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.104087_bib13","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3390\/ijms23073871","article-title":"The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy","volume":"23","author":"Maiorano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2026.104087_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101909","article-title":"PARP inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status","volume":"80","author":"Tomao","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2026.104087_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.jtho.2026.104087_bib16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2026.104087_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib21","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2023.06.013","article-title":"Durvalumab in combination with olaparib versus durvalumab alone as maintenance therapy in metastatic NSCLC: the phase 2 ORION study","volume":"18","author":"Ahn","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104087_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jtho.2024.10.026","article-title":"The phase 3 KEYLYNK-006 study of pembrolizumab plus olaparib versus pembrolizumab plus pemetrexed as maintenance therapy for metastatic nonsquamous NSCLC","volume":"20","author":"Gray","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"7_Suppl","key":"10.1016\/j.jtho.2026.104087_bib23","article-title":"Results from phase 3 KEYLYNK-008: pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)","volume":"84","author":"Hochmair","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.104087_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2023.2171783","article-title":"Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts","volume":"43","author":"Xue","year":"2023","journal-title":"J Obstet Gynaecol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642600540X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642600540X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:38:23Z","timestamp":1793947103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608642600540X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S155608642600540X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104087","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104087"}}